ACG 2014 Virtual Press Briefing: Hepatitis C
Philadelphia, PA (October 20, 2014)–Promising new research in the area of hepatitis C (HCV) therapy that suggests more patients, including those with cirrhosis, will be cured from this common cause of potentially fatal viral liver disease; as well as a number of abstracts that advance understanding of the safety and effectiveness of fecal microbiota transplantation for Clostridium difficile, are among the highlights of the American College of Gastroenterology's (ACG) 79th Annual Scientific Meeting , which will be held this week in Philadelphia. More than 4,000 gastroenterologists, physicians and other health care professionals from around the world will convene at the Pennsylvania Convention Center to review and present the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.
Newswise — This year the College offers a series of pre-recorded virtual press briefings which feature the insights of leading gastroenterology experts on several key abstracts that will be unveiled at ACG 2014 in the areas related to hepatitis C, inflammatory bowel disease, drug induced liver injury, nonalcoholic fatty liver disease, fecal microbiota transplantation and C. difficile.
Notable case reports related to protein shakes, chia seeds, and other supplementation where good health intentions go bad are also featured. In these briefings, ACG experts offer their perspectives on the significance of the findings in relation to the larger issues surrounding these GI-related topics as well as tips for clinicians and patients. Links to author commentary and the abstracts are available on this page for each abstract featured in the briefings.
Hepatitis C (HCV)
David E. Bernstein, MD, FACG and Paul Y. Kwo, MD, FACG provide insight on the following abstracts:
Listen to the briefing
Oral Paper 4 SVR12 (sustained virologic response 12 weeks post-treatment) of 99% Achieved with a Ribavirin-Free Regiment of ABT-450r Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients
Read author insight and access abstract
Oral Paper 5 Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients with Cirrhosis after Treatment With ABT -450/R/Ombitasvir, Dasabuvir and Ribavirin
Read author insight and access abstract
Media Interview Requests:
Press room and video recording facilities will be available onsite. To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000. From Sunday, October 19 - Wednesday, October 22, in ACG Press Room (Room 119A; Phone 215- 418-2358) at the Pennsylvania Convention Center in Philadelphia.
About the American College of Gastroenterology
Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of more than 12,000 individuals from 80 countries. The College's vision is to be the pre-eminent professional organization that champions the evolving needs of clinicians in the delivery of high quality, evidence-based, and compassionate health care to gastroenterology patients. The mission of the College is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation and advocacy in the areas of scientific investigation, education, prevention and treatment. www.gi.org. Visit the ACG Blog for all news, featured research and expert insights related to the annual scientific meeting. Follow ACG on Twitter and share your live updates #acg2014.
Links
Coverage @ Healio - Live coverage from ACG 2014 Annual Scientific Meeting in Philadelphia
Press Updates @ Newswise
Notable case reports related to protein shakes, chia seeds, and other supplementation where good health intentions go bad are also featured. In these briefings, ACG experts offer their perspectives on the significance of the findings in relation to the larger issues surrounding these GI-related topics as well as tips for clinicians and patients. Links to author commentary and the abstracts are available on this page for each abstract featured in the briefings.
Hepatitis C (HCV)
David E. Bernstein, MD, FACG and Paul Y. Kwo, MD, FACG provide insight on the following abstracts:
Listen to the briefing
Oral Paper 4 SVR12 (sustained virologic response 12 weeks post-treatment) of 99% Achieved with a Ribavirin-Free Regiment of ABT-450r Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients
Read author insight and access abstract
Oral Paper 5 Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients with Cirrhosis after Treatment With ABT -450/R/Ombitasvir, Dasabuvir and Ribavirin
Read author insight and access abstract
Media Interview Requests:
Press room and video recording facilities will be available onsite. To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000. From Sunday, October 19 - Wednesday, October 22, in ACG Press Room (Room 119A; Phone 215- 418-2358) at the Pennsylvania Convention Center in Philadelphia.
About the American College of Gastroenterology
Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of more than 12,000 individuals from 80 countries. The College's vision is to be the pre-eminent professional organization that champions the evolving needs of clinicians in the delivery of high quality, evidence-based, and compassionate health care to gastroenterology patients. The mission of the College is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation and advocacy in the areas of scientific investigation, education, prevention and treatment. www.gi.org. Visit the ACG Blog for all news, featured research and expert insights related to the annual scientific meeting. Follow ACG on Twitter and share your live updates #acg2014.
Links
Coverage @ Healio - Live coverage from ACG 2014 Annual Scientific Meeting in Philadelphia
Press Updates @ Newswise
I think it is ridiclous that we live in the RICHESTS Country in the WORLD and to have to pay this kind of money for our medicines .When they will send it to Africa for 900.00 and we pay 144,000.00.Why is it Americans all ways have to pay for all of the World...Only God knows the answer and those who are making excessive amounts of money off hard working people WILL Answer..
ReplyDelete